-38%

est. 2Y upside i

HealthcareSeries C

Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction.

Rank

#2190

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Colossal Biosciences presents a moderate upside opportunity, driven by its pioneering technology and strong competitive moat in a nascent, high-potential market.

Last updated: March 10, 2026

Bull (25%)+200%

Colossal successfully commercializes its genomic technologies in human health and agriculture, with spin-offs like Form Bio achieving significant market penetration. Breakthroughs in de-extinction projects generate massive public and scientific interest, attracting substantial partnerships and government funding, pushing valuation to over $30B.

Base (45%)+20%

Colossal continues to make scientific progress in de-extinction and genetic engineering, but commercial revenue from licensing and spin-offs grows steadily rather than explosively. The company maintains its market leadership in de-extinction, and its valuation sees a modest increase to around $12.4B as it approaches an IPO or strategic acquisition.

Bear (30%)-50%

Significant scientific or ethical challenges arise in de-extinction projects, leading to public backlash and increased regulatory scrutiny. Commercialization efforts struggle to generate substantial revenue, and the high capital intensity leads to further dilution or a down round, reducing the company's valuation to approximately $5.2B and significantly impacting common stock value.

Est. time to liquidity~3.5 years

Preference Stack Risk

moderate

Funding Intensity

6%

Investors hold approximately $555M in liquidation preferences ahead of common shareholders.

Dilution Risk

moderate

As a Series C+ company in a capital-intensive field, further funding rounds are likely, which could lead to additional dilution for existing equity holders.

Secondary Liquidity

active

An active secondary market exists, with shares trading at approximately a 23% discount to the Series C valuation, indicating some liquidity for early investors/employees.

Questions to Ask at the Interview

Strategic questions based on Colossal's data — designed to show you've done your homework.

  • 1

    “Given the scientific skepticism around 'de-extinction' versus genetic modification, how does Colossal plan to navigate public perception and ethical considerations as it moves closer to bringing species back?”

  • 2

    “With the valuation heavily reliant on future potential, what are the most immediate and concrete revenue streams Colossal is focusing on from its platform technologies (e.g., human health, agriculture) to justify its current market position?”

  • 3

    “Considering the significant capital raised and the long R&D cycles in biotech, what is the company's strategy for managing dilution for employees, and what are the anticipated milestones or triggers for a liquidity event within the next 3-5 years?”

Community

Valuation Sentiment

Our model estimates -38% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.